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ABSTRACT
Thrombotic thrombocytopenic purpura (TTP) is a rare clinical emergency that is 
characterized by features of microangiopathic hemolytic anemia and 
thrombocytopenia. The availability of effective therapy with therapeutic plasma 
exchange has decreased the mortality rate from 90 % to approximately 20%. The 
historical pentad of clinical features once thought to be needed to make the 
diagnosis include fever, anemia, renal failure, neurological findings and 
thrombocytopenia. Currently, clinical diagnosis is made by existence of 
thrombocytopenia and microangiopathic hemolytic anemia unexplained by 
other causes. The variety of clinical presentations and the lack of specific 
laboratory diagnostic criteria make the diagnosis of TTP highly dependent on a 
high index of clinical suspicion and can be easily missed. Early recognition and 
appropriate treatment with plasma exchange in clinical settings is very important 
and is frequently life saving. Current knowledge in the etiopathogenesis, 
epidemiology, trends in the diagnosis and treatment are reviewed herein.
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Résumé
Purpura Thrombopénique Thrombotique (PTT ) est l'une des rares cliniques 
d'urgence qui se caractérise par des fonctionnalités d' anémie hémolytique 
microangiopathique et la thrombocytopénie. La disponibilité de thérapies 
efficaces avec plasma thérapeutique exchange a diminué le taux de mortalité de 
90 % à environ 20 %.  La pentode historique des fonctions cliniques une fois jugé 
nécessaire pour faire le diagnostic de la fièvre, anémie, insuffisance rénale, 
troubles neurologiques et de thrombocytopénie. Actuellement, diagnostic 
clinique est faite par existence d'une thrombopénie et une anémie hémolytique 
microangiopathique  inexpliquées par d'autres causes. La variété des 
présentations cliniques et de l'absence de laboratoire spécifique critères de 
diagnostic faire un diagnostic des TTP hautement tributaires d'un indice élevé de 
suspicion clinique et peut être facilement manquer. Reconnaissance précoce et 
un traitement approprié avec le plasma exchange dans les réglages cliniques est 
très important et est souvent sauver la vie. connaissances actuelles dans la 
etiopathogenesis, l'épidémiologie, les tendances dans le diagnostic et le 
traitement sont examinées ici.
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INTRODUCTION
Thrombotic thrombocytopenic 
purpura (TTP) is a life threatening disease 
which was first described in 1925 by 
Moschcowitz as a disease characterized by 
the pathological findings of hyaline 
microthrombi in many organs (1). It was first 
described in a teenager who had a sudden 
death. She had an abrupt onset and rapid 
progression of petechiae, pallor, paralysis 
and coma. At that time Moschcowitz thought 
there was a powerful poison that had both 
agglutinative and hemolytic properties. 
Multiple reports of the same disease followed 
and by 1966, Amorosi and Ultmann 
described TTP as a classic pentad of 
thrombocytopenia, microangiopathic 
hemolytic anemia (MAHA), change in 
mental status, renal failure and fever (2, 9). 
In 1982, a defect in the processing of 
unusually large VWF was thought to be 
responsible for this disease (3,4). TTP is 
characterized by systemic platelet  
aggregation, organ ischemia, profound 
thrombocytopenia and fragmentation of red 
blood cells (2). The annual incidence of TTP 
syndrome in the United States is 4-11 cases 
per million individuals. It is more common in 
women between ages of 10 and 40. Incidence 
in blacks is nine times higher than in non-
blacks (3). TTP has been shown to occur with 
demonstrably higher incidence in blacks and 
patients with preexisting autoimmune 
diseases like systemic lupus erythematosus 
(5, 6).
Epidemiological studies on TTP in 
Nigeria are scarce presently. A recent review 
of literature on TTP in Nigeria yielded three 
case reports highlighting TTP associated 
with Systemic Lupus Erythematosus (SLE) 
(7) and TTP associated with staphylococcus 
aureus endocarditis (8). Various clinicians 
and researchers worked on different 
treatment methods and discovery of effective 
and current gold standard therapy actually 
preceded the full discovery of the 
etiopathogenesis of the disease (9).
With effective treatment with 
therapeutic plasma exchange (TPE), the 
mortality has decreased from 90% to 20% 
(10,11). In clinical situations where there is a 
high index of clinical suspicion of the 
disease, renal insufficiency and neurologic 
symptoms are now late manifestations (12).
CLASSIFICATION
TTP can be classified as congenital or 
acquired (13). It could also be classified as 
sporadic, intermittent and recurrent forms 
depending on the recurrence of the events 
(14,15).
A single acute episode describes the 
sporadic form while relapsing episodes with 
symptom free periods of months or years 
marks the intermittent forms. Frequent 
relapsing episodes recurring after regular 
symptom free intervals is seen in the 
recurrent forms which is usually familial (14, 
15, 16).
The acute forms could be further 
classified as acute sporadic, idiopathic TTP 
or TTP associated with other conditions.
Congenital TTP also known as Upshaw 
Shulman Syndrome (USS) or Familial 
Relapsing TTP is caused by a genetic defect 
in the adisintegrin and metalloproteinase 
with a thrombospondin type 1 motif, member 
13 (ADAMTS13) gene, which results in a 
severe deficiency of ADAMTS13 enzyme 
causing persistence of unusually large Von 
Willebrand factor (UL-VWF). This is a rare 
condition (17). Acquired Idiopathic TTP has 
been attributed to a severe ADAMTS13 
deficiency due to an Immunoglobulin G (Ig 
G) autoantibody. This is more common than 
the congenital type (18).
TTP can occur in association with 
autoimmune diseases, drugs like clopidogrel, 
cyclosporine, hematopoietic stem cell 
transplant, malignancy, infections, hormone 
replacement therapy and pregnancy (11).
PATHOPHYSIOLOGY OF TTP
TTP is defined by an underlying 
defect in adisintegrin and metalloproteinase 
with a thrombospondin type 1 motif, member 
13 (ADAMTS13) genes, which results in 
ADAMTS13 enzyme deficiency (6) 
ADAMTS13 is a metalloprotease that 
cleaves the tyr1605-Met1606 bond in the 
central A2 subunit of Von Willebrand Factor 
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(VWF) (7). VWF is synthesized primarily by 
the endothelial cells. ULVWF multimers are 
formed and are stored in the Weibel –Palade 
bodies or secreted into the plasma. They 
mediate platelet aggregation and collagen 
binding. These ULVWF multimers 
depolymerize under normal conditions and 
the enzyme responsible for this is 
ADAMTS13.A severe deficiency of this 
enzyme activity to <5-10% is an abnormality 
specific for TTP (15, 18).
ADAMTS13 cleaves Ultra-large 
multimers of VWF (ULVWF) within platelet 
aggregates under flowing conditions; this 
usually limits platelet thrombus formation. In 
TTP, since ADAMTS13 is either absent 
congenitally or absent due to autoantibodies, 
platelets adhere to these ULVWF causing 
systemic platelet aggregation with 
microvascular thrombosis and occlusion. 
(19) Microangiopathic hemolytic anemia 
(MAHA) occurs as blood flows through the 
microcirculation, which is partially occluded 
by platelet aggregates. Evidence of MAHA is 
indicated by the presence of schistocytes on a 
blood film examination and elevated LDH 
(20).
The basis of Plasma exchange for treatment is 
the replacement of the missing ADAMTS13 
enzyme and the removal of the inhibitory 
autoantibodies (20, 21).
CLINICAL FEATURES
Symptoms are nonspecific and can 
range from weakness, abdominal pain, 
bleeding, vomiting, and strokes, renal 
insufficiency. Occlusive ischemia of the 
brain or the GI tract or any organ can occur 
due to microvascular thrombi. Before the era 
of treatment, the pentad of fever, renal 
failure, thrombocytopenia and neurologic 
impairments were seen but are no longer 
needed for diagnosis. Typically otherwise 
unexplained MAHA evidenced by 
schistocytes and elevated LDH and 
thrombocytopenia strongly suggest the 
diagnosis (22).
DIFFERENTIAL DIAGNOSIS
These are often challenging since 
there are a number of disease conditions with 
thrombotic microangiopathy. Thrombotic 
microangiopathy can be seen in Post 
hematopoietic stem cell transplantation, HIV 
infection, HELLP syndrome, preeclampsia, 
medications like calcineurin inhibitors, 
ticlopidine, malignant hypertension, 
disseminated malignancy, vasculitis, 
catastrophic antiphospholipid syndrome. 
There are also TTP like syndromes including 
Hemolytic uremic syndrome (HUS) and 
atypical hemolytic uremic syndrome 
(aHUS).
HEMOLYTIC UREMIC SYNDROME 
(HUS)
This is defined as thrombotic 
microangiopathy associated with renal 
failure which typically occurs in children.
three forms have been identified (23).
Typical HUS; It is also known as diarrhea 
associated HUS (D+ HUS) and is rarely 
associated with ADAMTS13 deficiency. It 
occurs in about 80-90% of patients with 
HUS. Infections with Bacteria that produce 
Shiga toxins such as Escherichia coli 
O157:H7 have been implicated. Shiga like 
toxin mediated HUS has not been shown to 
respond to Plasma exchange therapy 
Atypical HUS: (D- HUS) or a HUS  is not 
associated with diarrhea and is seen in 10-
15% of cases .This is associated with 
dysregulation of complement pathway in 
60% of the patients .It has been shown to have 
limited response to TPE. It affects 
components of alternative complement 
pathway convertase C3bBb .A new drug, 
Eculizumab an anti-C5 complement 
monoclonal antibody has been approved for 
treatment of a HUS (24).
DEAP–HUS (deficiency of CFHR1 and 
CFHR3 proteins and autoantibody positive) 
HUS has been described. It is characterized 
by the presence of autoantibodies to central 
complement inhibitor factor H. The presence 
of DEAP-HUS was confirmed in the New 
Castle cohort where the frequency of deletion 
of CFHR1 and CFHR3 genes was around 
10% (23).
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DIAGNOSIS
The diagnostic criterion which 
includes thrombocytopenia and MAHA is 
present in many other syndromes making the 
diagnosis of TTP challenging (25). The value 
of  ADAMTS13 measurements  for  
establishing diagnosis and initiating 
treatment is uncertain (8). Patients can have 
ADAMTS13 deficiency and yet have 
nonspecific symptoms, while some patients 
will have the clinical symptoms and all the 
features of TTP without ADAMTS13 
deficiency. In nine cohort studies, the 
frequency of ADAMTS13 deficiency among 
patients with idiopathic TTP was 33-100% 
(26). In another study reported, 80-100% of 
pat ients  with Idiopathic TTP had 
undetectable ADAMTS13 level. 
In the Oklahoma registry, 9 of the 22 
patients with severe ADAMTS13 deficiency 
had no neurologic symptoms. They had 
nonspecific symptoms such as weakness; 
vomiting diarrhea (8). This makes the 
diagnosis challenging since many other 
diseases could have these symptoms as their 
presenting features. Other factors making the 
diagnosis even more challenging include 
discrepancies among the various assays and 
heterogeneous nature of the manifestations 
of TTP (8). Some syndromes other than TTP 
may have severe ADAMTS13 deficiency 
while some patients presenting with features 
of TTP may have normal levels of 
ADAMTS13 activity. There have been some 
studies suggesting that ADAMTS 13 assays 
may have a prognostic value. Patients with 
severe ADAMTS13 deficiency had a 
favorable prognosis when compared to those 
with detectable levels (11).
Zheng et al (11) noted that severe 
ADAMTS13 deficiency is associated with 
idiopathic TTP and low mortality, while TTP 
with detectable ADAMTS13 level is 
associated with high mortality. Those who 
have relapsing course of TTP are thought to 
be associated with ADAMTS13 deficiency 
caused by inhibitors (11). Therefore the key 
diagnostic clues are the presence of 
microangiopathic hemolytic anemia 
(presence of schistocytes on peripheral blood 
smear, increased LDH and decrease in serum 
haptoglobin) and thrombocytopenia in the 
absence of other causes like sepsis, 
d i s s e m i n a t e d  c a n c e r ,  m a l i g n a n t  
hypertension, disseminated intravascular 
coagulation. The heterogeneous nature of 
clinical manifestations of TTP makes it 
reasonable and important to follow up the 
patient even after the diagnosis is made. This 
is because continuous evaluation is necessary 
to rule out other causes of TTP.Ten percent of 
patients in the Oklahoma TTP-HUS registry 
were found to have other diagnosis other than 




Plasma exchange also known as 
therapeutic plasma exchange (TPE) is the 
only treatment with evidence on its 
effectiveness. TTP is a category I indication 
for TPE in the American Society for 
Apheresis Guidelines for initiation of plasma 
exchange (27). This is attributed to the 
removal of ADAMTS13 autoantibodies and 
replacement of ADAMT13 enzyme (2, 8).
 The Canadian Apheresis Group 
(CAG) in 1991 demonstrated that survival of 
TTP was improved with TPE compared with 
plasma infusion. They randomized patients 
to receive plasma exchange daily (1-1.5 
times the predicted plasma volume)with 
fresh frozen plasma or plasma infusion 
(30ml/kg of body weight for one day then 
15ml per kilogram per day), it demonstrated 
that survival at 6months among patients 
receiving plasma exchange as compared to 
plasma infusion was 78% and 63% 
respectively. It also showed initial higher 
response in the plasma exchange group 
within seven days and a lower rate of relapse 
than patients receiving plasma transfusion 
(10).
Even though plasma exchange is the 
standard treatment, plasma infusions could 
be used in patients in whom plasma exchange 
cannot be promptly started. It is also used for 
patients with severe or refractory disease 
between plasma exchange therapies and in 
Congenital TTP (17). In another study, there 
was no superiority in the use of cryo-
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supernatant plasma, which is deficient in 
VWF when compared to fresh frozen plasma 
as replacement fluid (28,29).
Zheng et al (11) reported that plasma 
exchange was effective in patients with no 
ADAMTS13 inhibitors when compared to 
those with demonstrable inhibitor at 
presentation. Those with severe ADAMTS13 
deficiency and a high titer inhibitor had more 
prolonged courses with more complications 
and required additional immunosuppressive 
treatment.
The recommended treatment is 
plasma exchange daily (1-1.5 times the 
predicted plasma volume) until platelet count 
is above 150,000 per cubic millimeter, and 
LDH near normal for 2-3 consecutive days. 
The role of tapering treatment over longer 
duration has not been studied prospectively 
but is used frequently. The British guidelines 
recommend glucocorticoid for all the 
patients with a diagnosis of TTP and they also 
recommend that plasma therapy be continued 
for a minimum of 2 days after the platelet 
count returns to normal (9).
Plasma exchange is not without risks. 
The prognosis of TTP without treatment is 
poor .The benefits associated with therapy 
outweigh the risks. In a cohort study of 
patients treated for TTP, it was noted that 
there were some catheter related and plasma 
related complications. Two percent of these 
patients died from catheter related 
complications 26 percent of the patients had 
plasma exchange related complications. 
These complications include catheter related 
infection, hypotension requiring dopamine 
and venous thrombosis (9).
Immunosuppressive therapy
It is thought that patients who have a 
high titer inhibitor may benefit from 
immunosuppressive regimen. The rationale 
is that plasma exchange only has a temporary 
effect since the disease has a presumed 
autoimmune basis (9, 27). These patients 
with high titer inhibitors may require not only 
g l u c o c o r t i c o i d s  b u t  a l s o  o t h e r  
immunosuppressive regimen like rituximab. 
It has also been noted that the duration of TPE 
required to achieve a durable response has 
decreased over the past 15yrs leading to a 
decrease in TPE related complications. This 
observation has supported the effectiveness 
of corticosteroids and rituximab. However 
there are no clinical trials to guide use of 
immunosuppressive agents.
In patients with relapses or 
exacerbations, Prednisone 1 – 2mg/kg daily 
until remission is achieved or 1gram methyl 
prednisone for 3days has been used (30). 
Small case series have suggested a benefit 
with more intensive therapy with rituximab, 
cyc lophosphamide ,  v inc r i s t ine  o r  
cyclosporine. Relapses are rare except in 
those with severe ADAMTS13 deficiency 
(11, 22, 30).
Splenectomy 
The removal of the spleen is thought 
to reduce the B cell mass capable of forming 
autoantibodies. A reduced relapse rate has 
been noted in patients with relapsing TTP 
who had splenectomy dur ing the  
hematologic remission. This was shown in 
small case series by Crowther MA et al (31, 
32). The recommended approaches for those 
in remission are close monitoring and prompt 
medical attention especially with symptoms 
that might suggest relapse. There is 
uncertainty in the efficacy of any treatment to 
prevent relapse.
Antiplatelet agents
Some people include the use of 
antiplatelet therapy in the management of 
TTP. There is some evidence in favor of this 
but it remains controversial. However it 
seems to be used currently in patients with 
neurological complications such as strokes or 
TIA (33).
Platelet transfusions
There has been reluctance to 
transfuse platelets in TTP. However when 
thrombocytopenia with overt hemorrhage is 
present or prevention of bleeding with a 
surgical procedure that involves a high risk 
bleeding is present, platelet transfusion may 
be reasonable (24).
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Relapse 
A TTP relapse defined as recurrent disease 
occurring 30 days after reaching therapeutic 
response has been found to be more likely in 
patients with ADAMTS13 activity<10% 
than among patients with ADAMTS13 of 
10% or more. Kremer et al noted that the 
relapse occurred within one year in patients 
with ADAMTS13 activity <10% as opposed 
to within 2 years in patients with 
ADAMTS13 >10%. There was no factor 
associated with relapse apart from male sex. 
He also noted that those treated with 
rituximab following relapse had no other 
relapses following treatment. Rituximab is 
being investigated and is not yet the standard 
treatment for relapse (21).
Emerging research areas 
Since the discovery of ADAMTS13 
as the enzyme implicated in TTP, there is a 
potential promising therapy in form of 
recombinant ADAMTS13. This has 
demonstrated the ability to overcome 
inhibitory ADAMTS13 autoantibodies in 
mouse models Inhibition of platelet- Von 
willebrand factor interaction to prevent 
micro vascular thrombosis represents an area 
that is being explored as potential therapeutic 
target. Other potential therapies that deserve 
e v a l u a t i o n  i n c l u d e  I n h i b i t o r s  o f  
polymerization of VWF multimers.
CONCLUSION
Thrombotic Thrombocytopenia is a 
disease that responds well to treatment but 
could be fatal if not treated. A high index of 
suspicion is needed and prompt initiation of 
therapeutic plasma exchange is needed. 
ADAMTS13 deficiency is not needed to 
make diagnosis or make decisions regarding 
initiation of therapy.
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Plasma exchange plus 
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therapy may be 
required.  








Typical in children 
with renal failure  
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** Thrombocytopenia and microangiopathic hemolytic anemia are part of the clinical findings.
 Adapted from Thrombotic thrombocytopenic purpura by James N George.
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Peripheral bloods smear showing schistocytes
 









   




for 2 consecutive days accompanied by 
normalizingLDH 
 Durable treatment response
 
This is treatment response that has lasted at least 
30days after discontinuation of plasma exchange
 Exacerbation
 
This describes disease recurrence
 
within 30 days 
after treatment response has been achieved.
 Relapse 
 





If there is no treatment response by day 30 post 
treatment and/or no durable treatment response by 
Day 60.
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